Kadimastem Approaches FDA To Begin Trials On ALS Treatment

October 6, 2014 | The Israeli regenerative medicine company Kadimastem reports that they approached the US Food & Drug Administration regarding a stem cell treatment it is developing for ALS. This is the first approach made by the company to the American drug approval body in which Kadimastem intends to consolidate a preliminary outline for its continuing trials on the ALS drug. The company recently posted positive results in a pre-clinical trial where the efficacy of injecting support cells (astrocytes) into the spinal fluid of ALS model mice was tested, increasing the life expectancy of the mice treated and seeing a significant improvement of their motor function. Kadimastem was co-founded by CEO Yossi Ben Yossef in 2009 together with Chief Scientist and winner of the Israel Prize, Prof. Michel Revel.